The Role of GLP-1 Receptor Agonists in the Management of Obesity

The role of GLP-1 receptor agonists in the management of obesity

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian health care system.

The enthusiasm for the new generation of anti-obesity drugs is causing an outbreak of investment in financial markets. In France, the government is to announce, on Monday 26 May, its wish to facilitate their access.

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biote…

Why I’m Bullish on Eli Lilly

GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That suppression of the urge to imbibe could affect the spirits and beer business.

Dublin – Patients at a medication weight loss clinic in Dublin, treated with the GLP-1 agonists liraglutide or semaglutide, not only lost several kilos of body weight but also lost their appetite for alcoholic beverages. Weekly alcohol consumption decreased, according to the results obtained in the run-up to the European Congress on Obesity (ECO2025) in...

GLP-1ra receptor agonists role in the management of obesity in Australia

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the Australian health care system.Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as living with obesity in 2022 and the cost of obe…